SILO Stock Overview
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Silo Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.71 |
| 52 Week High | US$12.45 |
| 52 Week Low | US$2.35 |
| Beta | -0.76 |
| 1 Month Change | 5.46% |
| 3 Month Change | -27.87% |
| 1 Year Change | -71.53% |
| 3 Year Change | -86.47% |
| 5 Year Change | n/a |
| Change since IPO | -97.70% |
Recent News & Updates
Shareholder Returns
| SILO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.5% | -0.8% | 1.7% |
| 1Y | -71.5% | 4.4% | -9.6% |
Return vs Industry: SILO underperformed the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: SILO underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| SILO volatility | |
|---|---|
| SILO Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SILO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SILO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 2 | Eric Weisblum | https://silopharma.com |
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. It is developing solutions to address various underserved conditions.
Silo Pharma, Inc. Fundamentals Summary
| SILO fundamental statistics | |
|---|---|
| Market Cap | US$8.49m |
| Earnings (TTM) | -US$3.31m |
| Revenue (TTM) | US$72.10k |
117.8x
P/S Ratio-2.6x
P/E RatioIs SILO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SILO income statement (TTM) | |
|---|---|
| Revenue | US$72.10k |
| Cost of Revenue | US$5.84k |
| Gross Profit | US$66.26k |
| Other Expenses | US$3.37m |
| Earnings | -US$3.31m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 91.90% |
| Net Profit Margin | -4,587.04% |
| Debt/Equity Ratio | 0% |
How did SILO perform over the long term?
See historical performance and comparison